enVVeno Medical Corporati...
(NVNO)
undefined
undefined%
At close: undefined
2.85
-0.28%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.
The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency.
Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg.
The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
enVVeno Medical Corporation
| Country | United States |
| IPO Date | May 31, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Robert A. Berman |
Contact Details
Address: 70 Doppler Irvine, California United States | |
| Website | https://www.envveno.com |
Stock Details
| Ticker Symbol | NVNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661053 |
| CUSIP Number | 29415J106 |
| ISIN Number | US29415J1060 |
| Employer ID | 33-0936180 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Berman | Chief Executive Officer & Director |
| Craig Thomas Glynn | Chief Financial Officer, Treasurer & Secretary |
| Dr. Hamed Alavi Ph.D. | Senior Vice President & Chief Technology Officer |
| Andrew Cormack | Chief Commercial Officer |
| Dr. Benedict Broennimann M.D. | Chief Medical Officer of Outside of United States |
| Dr. Marc H. Glickman M.D. | Senior Vice President & Chief Medical Officer |
| Sandy Prietto | Vice President of Marketing |
| Warren Hancock | Co-founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | DEF 14A | Filing |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 424B5 | Filing |
| Sep 27, 2024 | FWP | Filing |
| Sep 26, 2024 | 424B5 | Filing |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | S-8 | Filing |